文献速递关节外科

司美格鲁肽使用是否降低全膝关节置换术后的并发症与费用

Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?
PubMed 文献 · J Arthroplasty · 2023-06-04

本研究利用国家数据库回顾性分析合并糖尿病并接受全膝关节置换术的患者,将使用司美格鲁肽者与对照组进行倾向性评分匹配。结果显示司美格鲁肽组脓毒症、假体周围感染和再入院风险降低,但心肌梗死、急性肾损伤、肺炎和低血糖事件风险升高。

要点

  • 司美格鲁肽组脓毒症、假体周围感染和再入院风险低于对照组。
  • 司美格鲁肽组心肌梗死、急性肾损伤、肺炎和低血糖事件风险高于对照组。
  • 翻修和90天费用在司美格鲁肽组呈降低趋势,但未达统计学显著。

核心结论

  • 全膝关节置换术期间使用司美格鲁肽降低脓毒症、假体周围感染和再入院风险,但增加心肌梗死、急性肾损伤、肺炎和低血糖事件风险。

研究设计与样本

  • 回顾性查询国家数据库至2021年。
  • 合并糖尿病并接受全膝关节置换术的骨关节炎患者,司美格鲁肽组7051例,倾向性评分匹配对照组34524例。

主要发现

  • 司美格鲁肽组心肌梗死发生率1.0% vs 对照组0.7%(OR 1.49;P = .003)。
  • 司美格鲁肽组急性肾损伤发生率4.9% vs 对照组3.9%(OR 1.28;P < .001)。
  • 司美格鲁肽组肺炎发生率2.8% vs 对照组1.7%(OR 1.67;P < .001)。
  • 司美格鲁肽组低血糖事件发生率1.9% vs 对照组1.2%(OR 1.55;P < .001)。
  • 司美格鲁肽组脓毒症发生率0 vs 对照组0.4%(OR 0.23;P < .001)。

关键数值与推荐

  • 司美格鲁肽组假体周围感染发生率2.1% vs 对照组3.0%(OR 0.70;P < .001)。
  • 司美格鲁肽组再入院发生率7.0% vs 对照组9.4%(OR 0.71;P < .001)。
  • 司美格鲁肽组翻修发生率4.0% vs 对照组4.5%(OR 0.86;P = .02),未达统计学显著。
  • 司美格鲁肽组90天费用15291.66美元 vs 对照组16798.46美元(P = .012),未达统计学显著。
  • 多变量逻辑回归计算OR、95%CI和P值,Bonferroni校正后显著性阈值P < .003。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetes mellitus (DM) and obesity are associated with total knee arthroplasty (TKA) complications. Semaglutide, a medication for DM and weight loss, can potentially affect TKA outcomes. This study investigated whether semaglutide use during TKA demonstrates fewer: (1) medical complications; (2) implant-related complications; (3) readmissions; and (4) costs. METHODS: A retrospective query was performed using a National database to 2021. Patients undergoing TKA for osteoarthritis with DM and semaglutide use were successfully propensity score-matched to controls semaglutide = 7,051; control = 34,524. Outcomes included 90-day postoperative medical complications, 2-year implant-related complications, 90-day readmissions, in-hospital lengths of stay, and costs. Multivariate logistical regressions calculated odds ratios (ORs), 95% confidence intervals, and P values (P < .003 as significance threshold after Bonferroni correction). RESULTS: Semaglutide cohorts had higher incidence and odds of myocardial infarction (1.0 versus 0.7%; OR 1.49; P = .003), acute kidney injury (4.9 versus 3.9%; OR 1.28; P < .001), pneumonia (2.8 versus 1.7%; OR 1.67; P < .001), and hypoglycemic events (1.9 versus 1.2%; OR 1.55; P < .001), but lower odds of sepsis (0 versus 0.4%; OR 0.23; P < .001). Semaglutide cohorts also had lower odds of prosthetic joint infections (2.1 versus 3.0%; OR 0.70; P < .001) and readmission (7.0 versus 9.4%; OR 0.71; P < .001), and trended toward lower odds of revisions (4.0 versus 4.5%; OR 0.86; P = .02) and 90-day costs ($15,291.66 versus $16,798.46; P = .012). CONCLUSION: Semaglutide use during TKA decreased risk for sepsis, prosthetic joint infections, and readmissions, but also increased risk for myocardial infarction, acute kidney injury, pneumonia, and hypoglycemic events.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Magruder ML, Yao VJH, Rodriguez AN, et al. Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty? J Arthroplasty. 2023. PMID: 37279843. doi:10.1016/j.arth.2023.05.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。